December 22, 2021
December 22, 2021 –
The U.S. FDA has approved a new indication for Cosentyx® (secukinumab – Novartis)
to treat active enthesitis-related arthritis (ERA) in individuals who are at least
December 22, 2021
December 22, 2021 –
Leqvio® (inclisiran) is now FDA approved for use as an adjunct to diet and maximally
tolerated statin therapy to treat adults who have heterozygous familial
December 20, 2021
December 20, 2021 –
Caplyta® (lumateperone – Intra-Cellular Therapies) oral capsules are now approved to treat depressive episodes associated with bipolar I or II disorder (bipolar
December 20, 2021
December 20, 2021 –
Vocabria® (cabotegravir – ViiV Healthcare) tablets have been approved for use in at-risk adults and adolescents weighing at least 35kg (77 pounds) for short-term
December 17, 2021
December 17, 2022 –
Dartisla ODT (glycopyrrolate) orally disintegrating tablets have been approved for use as an adjunct to treatment for peptic ulcer in adults to reduce the
December 17, 2021
December 17, 2021 –
The U.S. FDA has approved Invagen Pharma's lanreotide subcutaneous injection as the first generic version of Ipsen's Somatuline® Depot (lanreotide)
November 19, 2021
November 19, 2021 – The U.S. FDA has expanded emergency use authorization (EUA) for the Pfizer/BioNTech and Moderna COVID-19 vaccines. They can now be used
November 19, 2021
November 19, 2021 – The U.S. FDA has approved VoxzogoTM (vosoritide) for injection to increase linear growth in pediatric patients at least five years of age who have